Search - tctmd.com

Displaying 301 - 320 of 638

Sort: Relevancy | Date

News Conference News ESC 2017

Anacetrapib Finds (Modest) Success Where All Other CETP Inhibitors Failed

Michael O'Riordan

August 29, 2017

News Conference News ESC 2017

P2Y12 Inhibitor Pretreatment Questioned in STEMI

Todd Neale

August 29, 2017

News Conference News ESC 2017

Dual Antithrombotic Approach in Patients With A-fib Undergoing PCI Boosted in RE-DUAL PCI

Todd Neale

August 27, 2017

News Conference News ESC 2017

ESC Updates Guidelines for Treating STEMI Patients

Michael O'Riordan

August 27, 2017

News Conference News ESC 2017

Latest Bivalirudin, Heparin Face-off in MI Cements Winner in Routine Practice: VALIDATE-SWEDEHEART

Shelley Wood

August 27, 2017

News Opinion Editor's Corner ESC 2017

ESC 2017: In Tragedy’s Wake, Cardiology’s Biggest Congress Forges On

Shelley Wood

August 18, 2017

News Daily News

Money-Back Guarantee for Evolocumab Has Little Impact on Cost-Effectiveness

Michael O'Riordan

August 08, 2017

News Daily News

Long-term Ticagrelor Post-MI of ‘Intermediate Value’: Cost-Effectiveness Study

Leah Lawrence

July 24, 2017

News Daily News

Black Men Have Twofold Higher Risk of Dying From First CHD Event

Michael O'Riordan

July 10, 2017

News Daily News

Use of DAPT Score Following PCI Validated in PRODIGY Study

Yael L. Maxwell

June 12, 2017

News Daily News

Triple Therapy Not Being Widely Used in A-fib Patients Undergoing PCI

L.A. McKeown

May 23, 2017

News Features

How Low Can You Go? Concerns Over Aggressive LDL Lowering Eased as PCSK9 Evidence Mounts

Michael O'Riordan

May 23, 2017

News Conference News EuroPCR 2017

Best Antiplatelet Therapy in Real-World PCI? European Registries Fuel the Debate

Caitlin E. Cox

May 22, 2017

News Daily News

Lipid-Rich Plaque in Nonculprit Regions of the Target Vessel Predicts Future MACE Risk

Caitlin E. Cox

May 15, 2017

News Daily News

$2 Billion Annual Price Tag for FOURIER-Eligible VA Patients on PCSK9 Inhibitor

Michael O'Riordan

May 12, 2017

News Daily News

‘Forgotten’ Patients With Mechanical Heart Valves Undergoing PCI Pose Clinical Conundrum

Todd Neale

April 27, 2017

News Daily News

Thirty-Day Readmission in Acute MI Not Linked With Hospital Care or Clinical Outcomes

Michael O'Riordan

April 27, 2017

News Daily News

Long-term MI Risk Among Stable CAD Patients: Some Clues From CORONOR

Shelley Wood

April 24, 2017

News Daily News

Who Should Get a Statin? Guidelines Don’t Match Up

Michael O'Riordan

April 20, 2017

News Daily News

ACC/AHA ‘Very High Risk’ Criteria Only Modestly Predict Recurrent Events

Michael O'Riordan

April 04, 2017

Advertisement

Anacetrapib Finds (Modest) Success Where All Other CETP Inhibitors Failed

P2Y12 Inhibitor Pretreatment Questioned in STEMI

Dual Antithrombotic Approach in Patients With A-fib Undergoing PCI Boosted in RE-DUAL PCI

ESC Updates Guidelines for Treating STEMI Patients

Latest Bivalirudin, Heparin Face-off in MI Cements Winner in Routine Practice: VALIDATE-SWEDEHEART

ESC 2017: In Tragedy’s Wake, Cardiology’s Biggest Congress Forges On

Money-Back Guarantee for Evolocumab Has Little Impact on Cost-Effectiveness

Long-term Ticagrelor Post-MI of ‘Intermediate Value’: Cost-Effectiveness Study

Black Men Have Twofold Higher Risk of Dying From First CHD Event

Use of DAPT Score Following PCI Validated in PRODIGY Study

Triple Therapy Not Being Widely Used in A-fib Patients Undergoing PCI

How Low Can You Go? Concerns Over Aggressive LDL Lowering Eased as PCSK9 Evidence Mounts

Best Antiplatelet Therapy in Real-World PCI? European Registries Fuel the Debate

Lipid-Rich Plaque in Nonculprit Regions of the Target Vessel Predicts Future MACE Risk

$2 Billion Annual Price Tag for FOURIER-Eligible VA Patients on PCSK9 Inhibitor

‘Forgotten’ Patients With Mechanical Heart Valves Undergoing PCI Pose Clinical Conundrum

Thirty-Day Readmission in Acute MI Not Linked With Hospital Care or Clinical Outcomes

Long-term MI Risk Among Stable CAD Patients: Some Clues From CORONOR

Who Should Get a Statin? Guidelines Don’t Match Up

ACC/AHA ‘Very High Risk’ Criteria Only Modestly Predict Recurrent Events

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content